Amylyx co-CEOs Justin Klee (L) and Josh Cohen

Amy­lyx, search­ing for post-ALS fu­ture, li­cens­es a GLP-1 drug

Sev­er­al months af­ter a ma­jor tri­al set­back forced Amy­lyx Phar­ma­ceu­ti­cals to pull its on­ly ap­proved drug from the mar­ket, the com­pa­ny is div­ing in­to the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.